COVID-19管理格局:发展中国家需要可负担的平台来生产安全有效的生物治疗药物和预防性药物
本文综述了COVID-19现有治疗和预防策略、当前采用的疫苗和单克隆抗体平台,以及弥合低收入和中等收入国家所面临差距的途径。作者认为采用酵母衍生的毕赤酵母(P. pastoris)技术有助于开发安全、经验证、易于放大且可负担的重组疫苗或单克隆抗体。
要点
- 全球需可负担且可及的疫苗和单克隆抗体技术以控制COVID-19大流行。
- 亚洲和非洲国家疫苗接种完成百分比低于西方国家,需紧急关注。
- 作者认为酵母衍生毕赤酵母技术可开发安全、可放大、可负担的重组疫苗或单克隆抗体。
核心结论
- 作者认为采用酵母衍生的毕赤酵母(P. pastoris)技术有助于开发安全、经验证、易于放大且可负担的重组疫苗或单克隆抗体。
- 作者认为多抗原疫苗方法和单克隆抗体鸡尾酒技术平台将作为有效武器对抗SARS-CoV-2变异株构成的威胁。
研究设计与样本
- 本文为综述文章,阐述COVID-19现有治疗和预防策略、当前采用的疫苗和单克隆抗体平台以及弥合低收入和中等收入国家所面临差距的途径。
主要发现
- 与西方国家相比,亚洲和非洲国家疫苗接种完成百分比更低,需紧急关注。
- 全球制造商产能、对先进国家供应疫苗或原材料的依赖、国家经济、有限的研究设施和物流可能是相关因素。
- 酵母衍生毕赤酵母平台的优势在于不需要专用或专门设施,利用现有生产设施即可成为可负担的选择,无需大量额外资本投资。
临床怎么用
- 作者认为采用酵母衍生的毕赤酵母(P. pastoris)技术有助于开发安全、经验证、易于放大且可负担的重组疫苗或单克隆抗体。
- 作者认为多抗原疫苗方法和单克隆抗体鸡尾酒技术平台将作为有效武器对抗SARS-CoV-2变异株构成的威胁。
- 作者认为使用此类技术成功开发疫苗和单克隆抗体将使这些国家在疫苗和单克隆抗体可及性方面实现自给自足。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To gain world-wide control over COVID-19 pandemic, it is necessary to have affordable and accessible vaccine and monoclonal antibody technologies across the globe. In comparison to the western countries, Asian and African countries have less percentage of vaccination done which warrants urgent attention. Global manufacturer production capacities, dependency on advanced nations for the supply of vaccines or the raw material, national economy, limited research facilities, and logistics could be the factors. This review article elaborates the existing therapeutic and prophylactic strategies available for COVID-19, currently adopted vaccine and monoclonal antibody platforms for SARS-CoV-2 along with the approaches to bridge the gap prevailing in the challenges faced by low- and middle-income countries. We believe adoption of yeast-derived P. pastoris technology can help in developing safe, proven, easy to scale-up, and affordable recombinant vaccine or monoclonal antibodies against SARS-CoV-2. This platform has the advantage of not requiring a dedicated or specialized facility making it an affordable option using existing manufacturing facilities, without significant additional capital investments. Besides, the technology platform of multiantigen vaccine approach and monoclonal antibody cocktail will serve as effective weapons to combat the threat posed by the SARS-CoV-2 variants. Successful development of vaccines and monoclonal antibodies using such a technology will lead to self-sufficiency of these nations in terms of availability of vaccines and monoclonal antibodies.
引用
- Pidiyar V, Kumraj G, Ahmed K, et al. COVID-19 management landscape: A need for an affordable platform to manufacture safe and efficacious biotherapeutics and prophylactics for the developing countries. Vaccine. 2022. PMID: 35914959. doi:10.1016/j.vaccine.2022.05.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。